oasis 1 trial oral semaglutide 50 mg obesity results oasis-1 nejm 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 Most viewed this week from – A Review of the Oral

rn ieriklerinde bitki tozu yerine standardize bitki zleri iermektedir

Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

The GLP1 mechanism of action is more than a tool for lowering glucoseits a central player in a complex system influencing body weight, cardiovascular outcomes, liver health, and possibly even brain function

Future Research Goals So far, most evidence comes from retrospective studies or case reports, not from large randomized clinical trials, says Tariq, who says that experts are still looking to understand: Whether GLP-1s directly reduce intestinal inflammation How GLP-1s interact with the immune system and the gut microbiome Whether they are as effective in people with active Crohns disease as with those in remission Current research findings show promise, but Tariq encourages her patients to view them as early signals instead of established treatments